Asian Journal of Case Reports in Medicine and Health

A Rare Case Report on Clinical Insights of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Vankodoth. Sireesha *

CMR College of Pharmacy, Medchal, India.

Y. Vidhya Reddy

CMR College of Pharmacy, Medchal, India.

Nalam Sai Phani Vikas

Gandhi Medical College, Hyderabad, India.

Rayeni Srujana

CMR College of Pharmacy, Medchal, India.

*Author to whom correspondence should be addressed.

---

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) CIDP is a rare and heterogenous autoimmune disorder of the peripheral nervous system that attacks myelin sheath around the peripheral nerves. It is characterized by muscle weakness and sensory deficits, numbness that can lead to significant neurological disability evolving over more than 8 weeks. Raised protein concentrations in CSF and heterogeneous slowing of nerve conduction are typical of the condition. Understanding of its pathophysiology has recently improved, although its causes remain unclear. Diagnosis is sometimes challenging and can require use of neuro imaging and nerve biopsy. The diagnosis is also  based on a combination of clinical examination findings, electrodiagnostic studies, and other supportive evidence. Recognizing CIDP and distinguishing it from other chronic polyneuropathies is important because many patients with CIDP are highly responsive to treatment with corticosteriods, immunosuppressive or immunomodulatory therapies. This case report summarizes the variants of CIDP, diagnosis and current treatment strategies.

Keywords: Chronic inflammatory demyelinating polyradiculoneuropathy, neuroinflammatory, autoimmune, guillain-barré syndrome, immunosupperessive, immunomodulatory

---

---

---

References

Querol, L et al., Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021;18:2222–2235. Available:https://doi.org/10.1007/s13311-021-01117-3

Hans-Peter Hartung et al., The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies, Neurotherapeutics 2022;19(3):864-873 ISSN 1878-7479.

Saad TC et al. Chronic inflammatory demyelinating polyneuropathy: A rare cause of falls. BMJ Case Rep. 2019 Dec 2;12(12):e231676. DOI: 10.1136/bcr-2019-231676. PMID: 31796460; PMCID: PMC7001711.

Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS. Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):973-85. DOI: 10.1136/jnnp-2014-309697. Epub 2015 Feb 12. PMID: 25677463; PMCID: PMC4552934.

Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27: 427–58. DOI:10.1016/0022-510X(76)90213-6

Sommer C, Koch S, Lammens M, et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005; 65:1924–9.

DOI:10.1212/01.wnl.0000188879.19900.b

Bosboom WM, van den Berg LH, De BL, et al. The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;53:837–45 DOI:10.1212/WNL.53.4.837.

Pollard JD, McCombe PA, Baverstock J, et al. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1986;13: 123–34. DOI:10.1016/0165-5728(86)90059-7

Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy: Where we are, where we should go. J Peripher Nerv Syst. 2014;19:2–13.

Nobile-Orazio E et al., Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. Expert Rev Neurother. 2017;17:755–765.

Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol. 2013 Jun;15(3):350-66.

Gogia B, Rocha Cabrero F, Khan Suheb MZ et al. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. [Updated 2023 Jun 1]. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; 2024.